Development of High-Specificity Fluorescent Probes to Enable Cannabinoid Type 2 Receptor Studies in Living Cells-Reference-Cited by-同舟云学术

Development of High-Specificity Fluorescent Probes to Enable Cannabinoid Type 2 Receptor Studies in Living Cells

Published:2020-09-09 Issue:40 Volume:142 Page:16953-16964
ISSN:0002-7863
Container-title:Journal of the American Chemical Society
language:en
Short-container-title:J. Am. Chem. Soc.

Author:

Sarott Roman C.¹^ORCID,Westphal Matthias V.¹,Pfaff Patrick¹^ORCID,Korn Claudia²,Sykes David A.³⁴,Gazzi Thais⁵,Brennecke Benjamin⁵,Atz Kenneth²,Weise Marie⁵,Mostinski Yelena⁵,Hompluem Pattarin³⁴,Koers Eline³⁴,Miljuš Tamara³⁴,Roth Nicolas J.⁶,Asmelash Hermon⁶,Vong Man C.³⁴,Piovesan Jacopo³⁴,Guba Wolfgang²,Rufer Arne C.²,Kusznir Eric A.²,Huber Sylwia²,Raposo Catarina²,Zirwes Elisabeth A.²,Osterwald Anja²,Pavlovic Anto²,Moes Svenja²,Beck Jennifer²,Benito-Cuesta Irene⁷,Grande Teresa⁷,Ruiz de Martı́n Esteban Samuel⁷,Yeliseev Alexei⁸,Drawnel Faye²,Widmer Gabriella²,Holzer Daniela²,van der Wel Tom⁹,Mandhair Harpreet¹⁰,Yuan Cheng-Yin¹¹,Drobyski William R.¹²,Saroz Yurii¹³,Grimsey Natasha¹³^ORCID,Honer Michael²,Fingerle Jürgen²,Gawrisch Klaus⁸,Romero Julian⁷,Hillard Cecilia J.¹⁴,Varga Zoltan V.⁸¹⁵,van der Stelt Mario⁹^ORCID,Pacher Pal⁸,Gertsch Jürg¹⁰,McCormick Peter J.⁶,Ullmer Christoph²,Oddi Sergio¹⁶¹⁷,Maccarrone Mauro¹⁷¹⁸,Veprintsev Dmitry B.³⁴^ORCID,Nazaré Marc⁵^ORCID,Grether Uwe²,Carreira Erick M.¹^ORCID

Affiliation:

1. Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Vladimir-Prelog-Weg 3, 8093 Zürich, Switzerland

2. Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland

3. Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham NG7 2UH, U.K.

4. Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands B15 2TT, U.K.

5. Leibniz-Institut für Molekulare Pharmakologie FMP, Campus Berlin-Buch, 13125 Berlin, Germany

6. William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, England

7. Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, 28223, Madrid, Spain

8. National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland 20852, United States

9. Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, 2333 CC, Leiden, The Netherlands

10. Institute of Biochemistry and Molecular Medicine, University of Bern, 3012 Bern, Switzerland

11. Department of Microbiology and Immunology, Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States

12. Department of Medicine, Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States

13. Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 1142 Auckland, New Zealand

14. Department of Pharmacology and Clinical Pharmacology, Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States

15. HCEMM-SU Cardiometabolic Immunology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1085 Budapest, Hungary

16. Faculty of Veterinary Medicine, University of Teramo, 64100 Teramo, Italy

17. European Center for Brain Research (CERC)/Santa Lucia Foundation, 00179 Rome, Italy

18. Department of Applied Clinical and Biotechnological Sciences, University of L’Aquila, 67100 L’Aquila, Italy

Funder

Eidgen?ssische Technische Hochschule Z?rich

Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung

Ministero dell?Istruzione, dell?Universit? e della Ricerca

Ministerio de Econom?a y Competitividad

Queen Mary University of London

Roche Holding AG

Publisher